N-(5-methylpyridin-2-yl)-2-morpholin-4-ylacetamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(5-methylpyridin-2-yl)-2-morpholin-4-ylacetamide
• 化学式: C₁₂H₁₇N₃O₂
• 分子量: 235.28
• InChiKey: DRPSBVAEEZHXEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] FUSED QUINOLINE COMPUNDS AS PI3K/MTOR INHIBITORS<br/>[FR] COMPOSÉS DE QUINOLÉINE FUSIONNÉS COMME INHIBITEURS DE PI3K/MTOR
  申请人：ADVENCHEN PHARMACEUTICALS LLC

  公开号：WO2017011363A1

  公开（公告）日：2017-01-19

  The present invention relates to the compounds of formula I, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with cancers associated with protein kinases, to their use as medicaments for use in the production of inhibition of mTor, pi3k reducing effects in warm¬ blooded animals such as humans.

  本发明涉及公式I的化合物，其制备方法，含有其作为活性成分的药物组合物，用于治疗与蛋白激酶相关的癌症疾病状态的方法，以及作为药物用于在温血动物（如人类）中产生对mTor、pi3k的抑制作用的用途。
• PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US20140213585A1

  公开（公告）日：2014-07-31

  This invention is directed to methods of treating diseases or conditions associated with JAK2 activity in a mammal comprising the administration of a compound of formula (I): where n, m, Y, R 1 , R 2 , R 3 , R 4 and R 5 are disclosed herein, or a pharmaceutically acceptable salt.

  本发明涉及用于治疗哺乳动物中与JAK2活性相关疾病或病症的方法，包括给予以下公式（I）的化合物或其药学上可接受的盐：其中n，m，Y，R1，R2，R3，R4和R5在此被披露。
• PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS
  申请人：DOMAINEX LIMITED

  公开号：US20160000784A1

  公开（公告）日：2016-01-07

  Compounds of the general formula (I) and salts thereof are useful in the treatment of diseases associated with aberrant activity of the protein kinases IKKε and/or TBK-1 in which one of V and W is N, and the other of V and W is C—H; and R 1 , R 2 , R 3 and R 4 are as defined in the specification. The invention also provides uses of the compounds and compositions containing them.

  通式（I）及其盐在治疗与蛋白激酶IKKε和/或TBK-1的异常活性相关的疾病方面具有用处，其中V和W中的一个是N，另一个是C-H；R1、R2、R3和R4如规范中定义。本发明还提供了化合物的用途和含它们的组合物。
• Fused quinoline compounds as PI3K/mTOR inhibitors
  申请人：ADVENCHEN PHARMACEUTICALS, LLC

  公开号：US10730878B2

  公开（公告）日：2020-08-04

  The present invention relates to the compounds of formula I, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with cancers associated with protein kinases, to their use as medicaments for use in the production of inhibition of mTor, pi3k reducing effects in warm¬blooded animals such as humans.

  本发明涉及式 I 的化合物、其制备工艺、含有它们作为活性成分的药物组合物、治疗与蛋白激酶相关的癌症有关的疾病状态的方法，以及它们作为药剂用于产生抑制 mTor、减少人等温血动物中 pi3k 作用的用途。
• FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS
  申请人：ADVENCHEN PHARMACEUTICALS, NANJING LTD.

  公开号：EP3169687B1

  公开（公告）日：2019-01-02